DIP2B as a Prognostic Biomarker and Immunotherapy Target: Insights from Pan-Cancer Analysis

Area of Science:

• Oncology
• Molecular Biology
• Bioinformatics

Background:

• The Disco-interacting protein 2 homolog B (DIP2B) gene encodes a protein with DNA methyltransferase and AMP-binding sites.
• While implicated in tumorigenesis, DIP2B's role in cancer diagnosis and prognosis is not fully understood.

Purpose of the Study:

• To investigate the diagnostic and prognostic significance of DIP2B across various cancer types.
• To explore the regulatory mechanisms and potential therapeutic implications of DIP2B in cancer.

Main Methods:

• Utilized comprehensive bioinformatics analysis of TCGA and GTEx databases.
• Employed tools including R, STRING, Cytoscape, TISIDB, cBioPortal, GSCALite, HPA, NetworkAnalyst, and CancerSEA.
• Performed transcription factor analysis and assessed correlations with immune cells.

Main Results:

• DIP2B expression was significantly elevated in multiple cancer types, with notable variations across immune and molecular subtypes.
• DIP2B was linked to various cancer-associated signaling pathways, demonstrating significant diagnostic and prognostic capabilities.
• Identified SP1, SP3, and HDAC1 as potential DIP2B regulators and found a positive correlation with central memory CD8 T cells.

Conclusions:

• DIP2B holds promise as a valuable prognostic biomarker in oncology.
• DIP2B may represent a novel therapeutic target for cancer immunotherapy due to its potential role in immune modulation.